Dr. Charles Newman to head Riverview wound center

Dr. Charles Newman has been appointed medical director for Riverview Wound Care and Hyperbaric Center.

Dr. Charles Newman

Newman, a specialist in general and vascular surgery, is a familiar face in Etowah County medicine, with more than 20 years of service to the community.

He attended the University of Alabama School of Medicine and completed his surgical residency at Georgia Baptist Medical Center in 1995.

Newman is on the board of directors for East Alabama Emergency Medical Services Inc. and is chairman of East Alabama Regional Trauma Advisory Council. He also has served as chief of surgery at Riverview Regional Medical Center.

Equinox Medical, LLC Halo MINI NPWT PUMP SYSTEM IS AFFORDABLE AND PORTABLE

Dr. Lucian Newman Jr., specialist in general, vascular surgery and wound care, and Dr. Steven Bayer, wound care specialist, also have joined the center’s medical staff. They collectively have more than 80 years of surgical and practice experience. They join Dr. William Beekley, general surgeon, at the center.

Lucian Newman has been in practice in Etowah County for more than 30 years. He graduated from the University of Alabama School of Medicine and completed his surgical residency at University Hospital in Birmingham in 1966. He has served as chief of staff at Riverview and also is a past president of the Alabama Chapter of the American College of Surgeons.

Bayer is a graduate of Vanderbilt University and received his medical degree and training through the Uniformed Services medical school in Bethesda, Md.

Barclays Reaffirms “Overweight” Rating for Smith & Nephew plc (SN)

Smith & Nephew plc (LON:SN)‘s stock had its “overweight” rating reiterated by analysts at Barclays in a research note issued to investors on Wednesday, MarketBeat.Com reports. They currently have a GBX 1,230 ($19.27) target price on the stock. Barclays’ price objective points to a potential upside of 10.51% from the company’s previous close.

Shares of Smith & Nephew plc (LON:SN) opened at 1113.00 on Wednesday. The stock has a 50 day moving average of GBX 1,151.94 and a 200-day moving average of GBX 1,143.46. Smith & Nephew plc has a 52-week low of GBX 881.00 and a 52-week high of GBX 1,216.00. The stock’s market capitalization is GBX 9.95 billion.

In other Smith & Nephew plc news, insider Barlow ,Ian acquired 153 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average cost of GBX 1,188 ($18.61) per share, for a total transaction of £1,817.64 ($2,848.07).

Other equities analysts have also issued reports about the company. Numis Securities Ltd upgraded Smith & Nephew plc to an “add” rating and set a GBX 1,242 ($19.46) price objective on the stock in a report on Monday, June 1st. JPMorgan Chase & Co. restated a “neutral” rating and issued a GBX 1,069 ($16.75) target price (up previously from GBX 1,040 ($16.30)) on shares of Smith & Nephew plc in a research note on Thursday, July 30th. Deutsche Bank reiterated a “buy” rating and set a GBX 1,250 ($19.59) price objective on shares of Smith & Nephew plc in a research note on Tuesday, July 21st. Berenberg Bank reissued a “buy” rating and set a GBX 1,275 ($19.98) target price on shares of Smith & Nephew plc in a report on Friday, July 31st. Finally, AlphaValue reaffirmed a “buy” rating and issued a GBX 1,304 ($20.43) price objective on shares of Smith & Nephew plc in a report on Thursday, July 2nd. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of GBX 1,217.15 ($19.07).

Smith & Nephew plc is a global medical devices business running in the markets for complex surgical apparatus, which includes complex wound management and orthopedic trauma reconstruction and sports medicine. The Business operates in two sections: Advanced Surgical Devices and Advanced Wound Management. The Company’s Advanced Surgical Devices (LON:SN) segment offers products and technologies, including orthopedic reconstruction, trauma and extremities, sports medicine joint repair, arthroscopy enabling technologies as well as other advanced surgical devices (ASD). The Business ‘s Advanced Wound Management (AWM) segment offers products, including Advanced Wound Care, Complex Wound Apparatus and Advanced Wound Bioactives. The Business runs throughout the entire world and has distribution channels in over 100 nations.
Smith & Nephew plc (LON:SN)‘s stock had its “overweight” rating reiterated by analysts at Barclays in a research note issued to investors on Wednesday, MarketBeat.Com reports. They currently have a GBX 1,230 ($19.27) target price on the stock. Barclays’ price objective points to a potential upside of 10.51% from the company’s previous close.

Shares of Smith & Nephew plc (LON:SN) opened at 1113.00 on Wednesday. The stock has a 50 day moving average of GBX 1,151.94 and a 200-day moving average of GBX 1,143.46. Smith & Nephew plc has a 52-week low of GBX 881.00 and a 52-week high of GBX 1,216.00. The stock’s market capitalization is GBX 9.95 billion.

In other Smith & Nephew plc news, insider Barlow ,Ian acquired 153 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average cost of GBX 1,188 ($18.61) per share, for a total transaction of £1,817.64 ($2,848.07).

Other equities analysts have also issued reports about the company. Numis Securities Ltd upgraded Smith & Nephew plc to an “add” rating and set a GBX 1,242 ($19.46) price objective on the stock in a report on Monday, June 1st. JPMorgan Chase & Co. restated a “neutral” rating and issued a GBX 1,069 ($16.75) target price (up previously from GBX 1,040 ($16.30)) on shares of Smith & Nephew plc in a research note on Thursday, July 30th. Deutsche Bank reiterated a “buy” rating and set a GBX 1,250 ($19.59) price objective on shares of Smith & Nephew plc in a research note on Tuesday, July 21st. Berenberg Bank reissued a “buy” rating and set a GBX 1,275 ($19.98) target price on shares of Smith & Nephew plc in a report on Friday, July 31st. Finally, AlphaValue reaffirmed a “buy” rating and issued a GBX 1,304 ($20.43) price objective on shares of Smith & Nephew plc in a report on Thursday, July 2nd. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of GBX 1,217.15 ($19.07).

Smith & Nephew plc is a global medical devices business running in the markets for complex surgical apparatus, which includes complex wound management and orthopedic trauma reconstruction and sports medicine. The Business operates in two sections: Advanced Surgical Devices and Advanced Wound Management. The Company’s Advanced Surgical Devices (LON:SN) segment offers products and technologies, including orthopedic reconstruction, trauma and extremities, sports medicine joint repair, arthroscopy enabling technologies as well as other advanced surgical devices (ASD). The Business ‘s Advanced Wound Management (AWM) segment offers products, including Advanced Wound Care, Complex Wound Apparatus and Advanced Wound Bioactives. The Business runs throughout the entire world and has distribution channels in over 100 nations.

Post Acute Care – Marketing Manager for Hire – Acelity

Acelity is a global wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. They are committed to advancing the science of healing and restoring people’s lives. Acelity has a reach across more than 75 countries; its innovative and complementary product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,500 people around the world.

To continue the growth and innovation of their first in class products, there is an opportunity for the role of:

Marketing Manager – Post-Acute (Wound Care)

Location: Home Office (anywhere in Europe)

Competitive Salary + excellent benefits

Responsibilities

  • Responsible for contributing towards the development and delivery of the Acelity Post-Acute Strategic Marketing plan
  • Work collaborative with all local marketing teams to gain understanding, adapt EU Strategy and drive execution in local markets.
  • Prepare and develop business marketing plans in line with the company goals and objectives, both in respect of revenues as well as market growth and penetration
  • Execute day-to-day management of product portfolio, including inventory management, forecasting, reporting, product improvement initiatives, and future product configurations.
  • Provide daily support and work closely with the sales team across Developed Markets including tools and strategies as appropriate
  • Develop Launch plans for future products including understanding or other applications, channels and devices
  • Ensure consistency of the brand across applications and geographies
  • Up to 50-60% travel across the Developed Markets

Requirements

  • Degree level or equivalent in Marketing or Healthcare related science is of advantage
  • Minimum of 3-5 years of Marketing Management experience
  • Possesses demonstrable and proven seasoned experience in marketing or clinical marketing for medical device or pharmaceutical firms
  • Experience in post-acute sales environment
  • Knowledge and understanding of reimbursement is advantageous
  • As a person you demonstrate strong interpersonal and influential skills
  • You are a highly motivated and driven individual, who exudes integrity, who works in a creative manner when formulating concepts.

If you feel that this is the right move for you and want to join a reputable and growing international business then please apply below or contact us at Mercuri Urval.

learn what 2000 calories looks like to prevent diabetes

It does appear to be true. NHS data confirms that an additional 1.2 million adults are living with diabetes in England and Wales now compared to figures in 2005. Most of this is type 2 diabetes which usually develops later in life, doesn’t necessarily require insulin and is often related to obesity, especially in those with an inherited tendency.

Diabetes UK predicts that if current trends continue, 5 million people will have diabetes by 2025. And care is suboptimal in 40% of diabetics who don’t receive all eight care processes that the National Institute for Health and Care Excellence recommends. Of the 100 amputations a week, 80% are thought to be preventable with optimal care.

Diabetes is a killer and a major cause of significant health problems: kidney failure, stroke, heart attacks and blindness. And it’s expensive. Diabetes wound treatment accounts for 10% of the annual NHS budget (about £10bn a year).

And the devil is that it is often – though not always – a preventable disease. The single biggest preventable factor is obesity. But of current trends continue, one in three of us will be obese by 2034 and one in 10 of us will be diabetic.

The NHS Diabetes Prevention Programme is aiming to introduce an evidence-based behavioural programme to fight this trend. It’s being developed and rolled out across the country.

Diabetes UK is also calling for more NHS resources to provide better care, avoid complications like amputations and give more “flexible education options” for people with diabetes.

Healthcare professionals are encouraged to identify individuals at particularly high risk of developing diabetes because they’re obese or have an inherited tendency, and offer specific intervention.

And there is growing awareness of the need to identify and intervene when young people are becoming obese and at risk of type 2 diabetes. There’s particular interest in trying to make sugary drinks more expensive, less attractive or less available, especially to young people.

But the only way that the tide will be turned is in a massive change in the way we lead our lives. Sport has to come back into schools, playing fields reclaimed and repurchased, cycling made safe and walking to school become the norm.

And we’re going to have to stop eating all the time. It’s not just what we eat (although clearly sugary drinks and calorie laden muffins are not helpful). It’s the way we have become a nation of constant grazers. Schools need to teach pupils what 2,000 calories a day looks and feels like. It means a breakfast of toast or cereal, a sandwich and zero calorie drink (like water) at lunch and a supper of protein, veg and a portion of carbohydrate like some boiled potatoes. Some fruit and a yoghurt, and you’re basically done for the day. Who eats like that nowadays?

The messages need to be clear and unambiguous. Public health policies and political intervention are all very well. But individuals need to know how to say no to the constant offers of food and sugary drinks that surround us. The temptations will always be there. We need the tools to resist.

Negative pressure wound therapy (NPWT)has been proven to help heal diabetic wounds.

halo mini npwt pump canister halo mini npwt user interface halo mini negative pressure wound therapy pump

Quebec strawberry has potential to reduce Type 2 diabetes risk

Quebec may be known for maple syrup and poutine, however maybe soon strawberries can be added to the rundown. A varietal known as the Authentic Orleans strawberry seems to help diminish the danger of creating Type 2 diabetes.

Developed on the Île d’Orléans—an island on the St. Lawrence River not a long way from downtown Québec City—the delicious, red berry contains a more prominent amassing of specific cancer prevention agents than conventional mixtures, its makers claim.

The strawberry was as of late the center of a clinical trial headed by researchers from Laval University and the Center hospitalier de l’Université Laval. Sixty individuals took an interest, expending either a concentrate rich in polyphenols got from cranberries and Authentic Orleans strawberries or a placebo over a six-week period.

The outcomes demonstrated that expending the Orleans-strawberry concentrate lessened insulin resistance by around 20 for each penny and enhanced glucose administration in stout individuals and those at danger of creating Type 2 diabetes.

“The clinical study demonstrated that the strawberries with cranberries decreased insulin resistance fundamentally,” says André Gosselin, educator of agriculture at Laval and co-proprietor of Les Fraises de l’île d’Orléans, in a telephone meeting with Yahoo Canada. “It could be a characteristic item to help individuals who are fat or who could get to be diabetic.”

The Orleans is another strawberry cultivar (a licensed hereditary choice of strawberry) described by abnormally elevated amounts of polyphenols, which go about as hostile to oxidants to ensure cells and body chemicals against harm brought on by free radicals. Joined with polyphenols of cranberries, those of the Orleans strawberry are being utilized as a part of an item called GlucoPhenol, which makers case could be a more secure different option for metformin, a regularly utilized medication to treat Type 2 diabetes that helps control blood-glucose levels.

Despite the fact that metformin might likewise lessen the danger of building up the illness among individuals who are at danger, it can bring about symptoms, for example, lactic acidosis—a possibly life-debilitating condition- – and gastrointestinal issues.

While strawberries and strawberry concentrate may be useful to individuals with or at danger of diabetes, Joanne Lewis, chief of diabetes training at the Canadian Diabetes Association, suggests alert, as more research is required.

As per the Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes, Natural Health Products (NHPs)— which incorporate home grown drugs, vitamins, minerals and other fundamental supplements, probiotics and numerous other normally happening substances—are generally utilized, yet the confirmation of their viability in the counteractive action of diabetes is obscure.

Wound Care fastest growing negative pressure wound therapy pump company in the USA and Europe.

“Polyphenols and cell reinforcements are promising exacerbates that may help to control oxidative anxiety and aggravation, which may assume a part in lessening insulin resistance and the complexities of diabetes,” Lewis tells Yahoo Canada. “The long haul wellbeing and viability of these mixes are of concern. Nonetheless, it’s urging to see investigate that shows guarantee.”

Lewis says that the most ideal approach to diminish the danger of diabetes is to receive enhanced way of life propensities that outcome in a five to seven for every penny weight reduction through customary physical movement and good dieting.

All things considered, strawberries still make a decent nibble.

“When all is said in done, strawberries are an extraordinary decision for individuals with diabetes and individuals at danger for creating diabetes,” Lewis says. “A two-glass serving contains around 15 grams of accessible starch, contrasted with other organic product where a much littler part gives an equivalent

Halo XT NPWT Pump System

Northwest Florida Community Hospital Wound Healing Institute Celebrated 5th year anniversary

CHIPLEY – Northwest Florida Community Hospital’s Wound Healing Institute commended its five year commemoration Thursday, July 30. Guests were dealt with to refreshments and a voyage through the middle amid a drop-in style open house.

The organization opened its entryways in August 2010, conveying an end to a constrained drive for some zone inhabitants offering so as to look for tend to ceaseless injuries modified treatment regimens, complete treatments, and the most recent techniques and gear, including hyperbaric oxygen treatment.

Equinox Medical, LLC is a fastest growing negative pressure wound therapy pump and black foam wound dressing kit manufacturer.

FREE WEBINAR: BRIDGING TWO WOUNDS USING BLACK FOAM DRESSING WEBINAR BY JOEY MALLARI

Bridging two wound using black foam dressing webinar

Topic: Bridging two wounds using NPWT Black Foam Dressing Kit by Equinox Medical

When: August 25, 2015

Time: 10:00 AM Eastern Standard Time

Hosted by: Holly Desimone, RN, BSN, WCC and Joey Mallari

REGISTER NOW

 

While HALO MINI NPWT PUMP SYSTEM .® Therapy might at first appear to be more lavish, the clinical advantages might really help offices bring down their general expense of consideration. You can take in more about HALO MINI NPWT PUMP SYSTEM . Treatment’s shown cost viability.

 

Will you treat more than one injury with one treatment unit?

 

Can a doctor’s facility bill for HALO MINI NPWT PUMP SYSTEM . Treatment?

 

Cloth or froth dressings. Arrives a distinction?

 

Will you treat more than one injury with one treatment unit?

 

Yes. EQUINOX MEDICAL has set up two systems for joining injuries to one treatment unit: “Spanning” and “Y connecting.”

 

Spanning can be refined when you have numerous injuries of comparative pathology in close nearness to each other. The HALO MINI NPWT PUMP SYSTEM .® wrap is put on the in place skin in the middle of wounds, and a portion of froth is set from one injury bed to the next over the hung skin. The length of all bits of froth are touching one another, you can put the tubing in a focal area and utilize one pump to disseminate weight all through every one of the injuries.

 

Y connecting permits you to treat numerous, non-contaminated injuries that are a bigger separation separated by utilizing a connector that can bolster two different tubing associations. Negative weight in either circumstance is disseminated over the injuries, yet controlled by one pump.

 

If it’s not too much trouble reference the HALO MINI NPWT PUMP SYSTEM . Treatment Clinical Guidelines for more

The organization reported ($0.37) income per offer (EPS) for the quarter, hitting the agreement appraisal of ($0.37),

Macrocure (NASDAQ:MCUR) issued its quarterly income results on Tuesday. The organization reported ($0.37) income per offer (EPS) for the quarter, hitting the agreement appraisal of ($0.37), AnalystRatingsNetwork.com reports. Amid the same quarter a year ago, the organization posted ($0.59) EPS.

Shares of Macrocure (NASDAQ:MCUR) exchanged down 1.08% on Tuesday, coming to $13.69. 10,272 shares of the organization’s stock exchanged hands. The organization has a 50 day moving normal cost of $13.66 and a 200 day moving normal cost of $11.04. Macrocure has a 52 week low of $6.82 and a 52 week high of $16.10. The company’s business sector capitalization is $228.73 million.

Halo XT NPWT Brochure

Independently, Oppenheimer set a $20.00 target cost on shares of Macrocure and gave the stock a “purchase” rating in an exploration report on Wednesday, May thirteenth. Five examiners have evaluated the stock with a purchase rating, The organization at present has an agreement rating of “Purchase” and a normal value focus of $16.40.

Macrocure Ltd is an Israel-based regenerative prescription organization. The Company is centered around creating, assembling and commercializing cell treatment items to address unmet needs in the treatment of perpetual and other difficult to-mend wounds. Its item applicant, CureXcell, is a propelled injury care (NASDAQ:MCUR), treatment to treat such injuries by infusing living human white platelets that have been enacted to encourage the mending procedure. CureXcell is an injectable suspension of living human white platelets, including macrophages, neutrophils and lymphocytes, that are pivotal to starting, advancing and finishing the procedure of cell recovery and wound mending. The Company utilizes its cell enactment innovation to trigger these cells to discharge development components and other biochemical variables that enhance the recuperating environment in the injury quaint little inn wound conclusion.